Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger neuroscience pharma company.

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of ...

Wall Street stocks were mixed after a choppy session as traders digested better-than-expected inflation data and looked ahead to bank earnings.

"The view out there in the analyst community is that the future of Biogen depends on the next deal that we do and that's not ...

Health-care companies rose amid deal activity. Shares of mental-illness drug developer Intra-Cellular rallied after health-care conglomerate Johnson & Johnson agreed to buy it for $15 billion, ...

Key Takeaways Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares.